238 related articles for article (PubMed ID: 21892086)
1. Pediatric ependymomas: will molecular biology change patient management?
Grill J; Bergthold G; Ferreira C
Curr Opin Oncol; 2011 Nov; 23(6):638-42. PubMed ID: 21892086
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
3. Pediatric ependymoma: biological perspectives.
Kilday JP; Rahman R; Dyer S; Ridley L; Lowe J; Coyle B; Grundy R
Mol Cancer Res; 2009 Jun; 7(6):765-86. PubMed ID: 19531565
[TBL] [Abstract][Full Text] [Related]
4. Genetic expression profiles of adult and pediatric ependymomas: molecular pathways, prognostic indicators, and therapeutic targets.
Nagasawa DT; Trang A; Choy W; Spasic M; Yew A; Zarinkhou G; Garcia HM; Yang I
Clin Neurol Neurosurg; 2013 Apr; 115(4):388-99. PubMed ID: 23374238
[TBL] [Abstract][Full Text] [Related]
5. Pediatric Ependymoma.
Vitanza NA; Partap S
J Child Neurol; 2016 Oct; 31(12):1354-66. PubMed ID: 26503805
[TBL] [Abstract][Full Text] [Related]
6. Ependymomas of the adult: molecular biology and treatment.
Rudà R; Gilbert M; Soffietti R
Curr Opin Neurol; 2008 Dec; 21(6):754-61. PubMed ID: 18989122
[TBL] [Abstract][Full Text] [Related]
7. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
Puget S; Grill J; Valent A; Bieche I; Dantas-Barbosa C; Kauffmann A; Dessen P; Lacroix L; Geoerger B; Job B; Dirven C; Varlet P; Peyre M; Dirks PB; Sainte-Rose C; Vassal G
J Clin Oncol; 2009 Apr; 27(11):1884-92. PubMed ID: 19289631
[TBL] [Abstract][Full Text] [Related]
8. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.
Lukashova-v Zangen I; Kneitz S; Monoranu CM; Rutkowski S; Hinkes B; Vince GH; Huang B; Roggendorf W
Acta Neuropathol; 2007 Mar; 113(3):325-37. PubMed ID: 17265049
[TBL] [Abstract][Full Text] [Related]
9. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
10. Ovarian ependymomas of extra-axial type or central immunophenotypes.
Stolnicu S; Furtado A; Sanches A; Nicolae A; Preda O; Hincu M; Nogales FF
Hum Pathol; 2011 Mar; 42(3):403-8. PubMed ID: 21195452
[TBL] [Abstract][Full Text] [Related]
11. Current therapy and the evolving molecular landscape of paediatric ependymoma.
Khatua S; Ramaswamy V; Bouffet E
Eur J Cancer; 2017 Jan; 70():34-41. PubMed ID: 27866097
[TBL] [Abstract][Full Text] [Related]
12. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
13. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients.
Korshunov A; Golanov A; Sycheva R; Timirgaz V
Cancer; 2004 Mar; 100(6):1230-7. PubMed ID: 15022291
[TBL] [Abstract][Full Text] [Related]
14. Put away your microscopes: the ependymoma molecular era has begun.
Mack SC; Taylor MD
Curr Opin Oncol; 2017 Nov; 29(6):443-447. PubMed ID: 28885433
[TBL] [Abstract][Full Text] [Related]
15. Molecular staging of intracranial ependymoma in children and adults.
Korshunov A; Witt H; Hielscher T; Benner A; Remke M; Ryzhova M; Milde T; Bender S; Wittmann A; Schöttler A; Kulozik AE; Witt O; von Deimling A; Lichter P; Pfister S
J Clin Oncol; 2010 Jul; 28(19):3182-90. PubMed ID: 20516456
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues.
Delgado-López PD; Corrales-García EM; Alonso-García E; García-Leal R; González-Rodrigálvarez R; Araus-Galdós E; Martín-Alonso J
Clin Transl Oncol; 2019 Nov; 21(11):1450-1463. PubMed ID: 30868390
[TBL] [Abstract][Full Text] [Related]
17. Management of Ependymoma in Children, Adolescents and Young Adults.
Thorp N; Gandola L
Clin Oncol (R Coll Radiol); 2019 Mar; 31(3):162-170. PubMed ID: 30616927
[TBL] [Abstract][Full Text] [Related]
18. [Pediatric ependymomas: Current diagnosis and therapy].
Frappaz D; Vasiljevic A; Beuriat PA; Alapetite C; Grill J; Szathmari A; Faure-Conter C
Bull Cancer; 2016 Oct; 103(10):869-879. PubMed ID: 27717499
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis.
Palm T; Figarella-Branger D; Chapon F; Lacroix C; Gray F; Scaravilli F; Ellison DW; Salmon I; Vikkula M; Godfraind C
Cancer; 2009 Sep; 115(17):3955-68. PubMed ID: 19536879
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers in pediatric glial tumors: a needed wind of change.
Fontebasso AM; Bechet D; Jabado N
Curr Opin Oncol; 2013 Nov; 25(6):665-73. PubMed ID: 24097106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
